Data as of May 17
| +0.41 / +1.26%|
The 8 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 40.00, with a high estimate of 50.00 and a low estimate of 33.00. The median estimate represents a +21.43% increase from the last price of 32.94.
The current consensus among 11 polled investment analysts is to Buy stock in Acorda Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.